Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort
Giovanni Torsello,Konstantinos Stavroulakis,Marianne Brodmann,Antonio Micari,Gunnar Tepe,Pierfrancesco Veroux,Andrew Benko,Donghoon Choi,Frank E G Vermassen,Michael R Jaff,Jia Guo,Reka Dobranszki,Thomas Zeller,IN.PACT Global Investigators,Patrick Peeters,Dierk Scheinert,Marc Bosiers,Lieven Maene,Dai-Do Do,Jeroen Hendriks,Koen Keirse,Bela Merkely,Jan-Willem Lardenoije,Zoltan Ruzsa,Britta Vogel,Joao Albuquerque E Castro,Daniel Periard,Tomasz Ludyga,Dominique Midy,Wouter Lansink,Dominik Ketelsen,Steven Dubenec,Martin Banyai,Nabil Chakfe,Franz Xaver Roithinger,Carlo Trani,Hossam Mansour,Seung-Woon Rha,Frank Vermassen,Alexander Belenky,Lubomir Spak,Nicholas Chalmers,Steven Kum,Je Hwan Won,Matej Vozar,Kong Teng Tan,Mamdouh Labib,Gert-Jan de Borst,Young-Soo Do,Joep Teijink,Juan Fernando Gomez,Aleksander Falkowski,Luis Ferreira,Jozef Matela,Seung-Whan Lee,Bart Verhoeven,Dalit Mannheim,Franco Nessi,Ivan Vulev,Jean-Paul de Vries,Radovan Maly,Zaza Kavteladze,Douglas Turner,Oscar Mendiz,Ralf Kolvenbach,Dimitrios Karnabatidis,Cesar Cuellar,Maarit Venermo,Linas Velicka,Goran Lundberg
DOI: https://doi.org/10.1177/1526602820931477
Abstract:Purpose: To report the 36-month outcomes from the prospective, multicenter, single-arm IN.PACT Global Study (ClinicalTrials.gov identifier NCT01609296) evaluating the performance of the IN.PACT Admiral drug-coated balloon (DCB) in real-world patients with femoropopliteal occlusive disease. Materials and Methods: The IN.PACT Global Study was conducted at 64 international sites and enrolled 1535 patients with complex lesions, which included bilateral disease, multiple lesions, de novo in-stent restenosis, long lesions, and chronic total occlusions. The predefined full clinical cohort included 1406 patients (mean age 68.6 years; 67.8% men) with claudication or rest pain treated with the study DCB. Mean lesion length was 12.09±9.54 cm; 18.0% had in-stent restenosis, 35.5% were totally occluded, and 68.7% were calcified. Freedom from clinically-driven target lesion revascularization (CD-TLR) was evaluated through 36 months. The safety composite endpoint was freedom from device- and procedure-related death through 30 days and freedom from major target limb amputation and clinically-driven target vessel revascularization within 36 months. All safety and revascularization events were reviewed by an independent clinical events committee. Results: The Kaplan-Meier estimate of freedom from CD-TLR through 36 months was 76.9%. The composite safety endpoint was achieved in 75.6% of patients. The 36-month all-cause mortality rate was 11.6%, and the major target limb amputation rate was 1.0%. The Kaplan-Meier estimate of freedom from CD-TLR through 36 months was significantly lower in patients with chronic limb-threatening ischemia (CLTI) compared with claudicants (67.6% vs 78.0%; p=0.003). Lesions affecting both the superficial femoral artery (SFA) and popliteal artery had lower Kaplan-Meier freedom from CD-TLR through 36 months (69.2%) than either isolated SFA (79.7%) or popliteal artery lesions (76.5%; log- rank p<0.001). Predictors of CD-TLR through 36 months included increased lesion length, reference vessel diameter ≤4.5 mm, in-stent restenosis, bilateral disease, CLTI, and hyperlipidemia. Conclusion: DCB angioplasty with the IN.PACT Admiral DCB for femoropopliteal disease in a diverse and complex real-world population is associated with sustained clinical efficacy and low rates of reinterventions at 3 years after the initial procedure.